

Dear ....

We are pleased to inform you that Pharming Group N.V. has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets.

Pharming will be the responsible partner to commercialize and distribute RUCONEST® in Hungary from **1<sup>st</sup> June 2020**, we would like to welcome you to Pharming!

In order to ensure that existing RUCONEST® patients can continue to receive their therapy, Pharming will be cooperating with PHOENIX Pharma Gyógyszerkereskedelmi Zrt. who will be responsible for distribution in Hungary. Sobi, PHOENIX Pharma Gyógyszerkereskedelmi Zrt. and Pharming will do everything possible to ensure that the transition is seamless and that the medical community and patients under treatment do not face any issues linked to this handover.

Should there be any questions, please do not hesitate to contact us:

**General contact:**

Dora Kekesi  
D.Kekesi@pharming.com  
+31 6 1319 1869

**Medical contact:**

Dr. Tobias Suiter, MD  
Vice President Medical Affairs  
T.Suiter@pharming.com  
+49 152 9000 7187

**Pharmacovigilance contact:**

safety.hu@pharming.com

We are looking forward to our journey together!

Yours sincerely,